| 5.51 -0.05 (-0.9%) | 09-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.84 | 1-year : | 11.28 |
| Resists | First : | 7.57 | Second : | 9.65 |
| Pivot price | 5.3  |
|||
| Supports | First : | 4.19 | Second : | 3.49 |
| MAs | MA(5) : | 5.68  |
MA(20) : | 5.77 |
| MA(100) : | 8.85 |
MA(250) : | 7.45 |
|
| MACD | MACD : | -1 |
Signal : | -1.2 |
| %K %D | K(14,3) : | 69 |
D(3) : | 58.5 |
| RSI | RSI(14): 37.5 |
|||
| 52-week | High : | 28.6 | Low : | 1.3 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ARTL ] has closed below upper band by 37.2%. Bollinger Bands are 75.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 5.56 - 5.6 | 5.6 - 5.63 |
| Low: | 5.09 - 5.14 | 5.14 - 5.18 |
| Close: | 5.44 - 5.51 | 5.51 - 5.56 |
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences, Inc. has research collaboration with Trinity College Dublin to investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
Fri, 05 Sep 2025
Artelo Biosciences Closes $3 Mln Public Offering Of Common Stock And Pre-Funded Warrants - Nasdaq
Fri, 05 Sep 2025
Artelo Biosciences Announces Closing of $3.0 Million Public Offering - GlobeNewswire
Thu, 04 Sep 2025
Artelo Biosciences Prices $3 Mln Public Offering Of Common Stock And Warrants - Nasdaq
Thu, 04 Sep 2025
$3 Million Capital Raise: Clinical-Stage Biotech Artelo Prices Public Offering for Cancer & Pain Research - Stock Titan
Wed, 03 Sep 2025
Artelo Biosciences Announces Proposed Underwritten Public Offering - GlobeNewswire
Wed, 03 Sep 2025
Clinical-Stage Pharma Artelo Biosciences Launches New Public Stock Offering via R.F. Lafferty - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 2 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 0.3 (%) |
| Held by Institutions | 1.5 (%) |
| Shares Short | 22 (K) |
| Shares Short P.Month | 18 (K) |
| EPS | -18.94 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -2 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -103.9 % |
| Return on Equity (ttm) | -356.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -5 (M) |
| Levered Free Cash Flow | -1 (M) |
| PE Ratio | -0.3 |
| PEG Ratio | 0 |
| Price to Book value | -2.76 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.98 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|